China SXT PharmaceuticalsSTU:2RY1 27 Days Payable is 255.79 as of Mar. 2026, which is 21% below its 10-year median of 321.86. GuruFocus rates STU:2RY1 with a GF Score™ of 27/100 and a GF Value™ of €321.31. The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, China SXT Pharmaceuticals ranks better than 89.37% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2RY1 vs CABR, BFRI, BIOE: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's Days Payable falls into.
China SXT Pharmaceuticals Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
China SXT Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China SXT Pharmaceuticals (STU:2RY1) has a Days Payable of 255.79 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China SXT Pharmaceuticals and its competitors. This is 21% below median its historical median of 321.86. Over the past decade, China SXT Pharmaceuticals' Days Payable has ranged from 179.66 to 397.17. According to the industry distribution chart, China SXT Pharmaceuticals ranks #98 out of 922 companies in the Drug Manufacturers industry, placing it in the top 10.6%.
Is China SXT Pharmaceuticals' Days Payable too high?
China SXT Pharmaceuticals' current Days Payable of 255.79 is 21% below median its 10-year median of 321.86. Over the past 10 years, this metric has ranged from a low of 179.66 to a high of 397.17. The Drug Manufacturers industry median Days Payable is 90.84. China SXT Pharmaceuticals' value of 255.79 is 181.6% above this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #98 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Days Payable compare to CABR and BFRI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #98 out of 922 companies for Days Payable. This places China SXT Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. China SXT Pharmaceuticals' value of 255.79 is 181.6% above this benchmark. Historically, China SXT Pharmaceuticals' own Days Payable has ranged from 179.66 to 397.17 over the past decade. While the company's 10-year median is 321.86 vs. the industry median of 90.84, China SXT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current Days Payable of 255.79 is 181.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current Days Payable is 255.79, which is 21% below median its own 10-year median of 321.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (STU:2RY1) has a current Days Payable of 255.79. The stock's GF Value™ is €321.31, compared to a current price of €384.00 — trading 19.5% above its estimated fair value. The current Days Payable is 255.79, which is 21% below median its 10-year median of 321.86 and 181.6% above the Drug Manufacturers industry median of 90.84. China SXT Pharmaceuticals' overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For China SXT Pharmaceuticals (STU:2RY1), the current Days Payable is 255.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China SXT Pharmaceuticals (STU:2RY1) Overvalued in 2026?
Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be overvalued.
The current stock price of €384.00 is trading 19.5% above its estimated GF Value™ of €321.31.
Key valuation signals for STU:2RY1:
Days Payable: 255.79 (21% below median its 10-year median of 321.86)
GF Value™: €321.31 vs. price of €384.00 (19.5% above fair value)
Industry Position: 181.6% above the Drug Manufacturers median (#98 of 922)
No single metric tells the full story. See the STU:2RY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
27GF Score
Get the complete analysis for STU:2RY1
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2RY1 has been successfully added to your 
